Athenex Announces Jeffrey Yordon to Lead Newly Formed Specialty Products Division

Buffalo, NY and Hong Kong– Athenex, Inc. announced today that Jeffrey Yordon has joined the Company as President of the newly formed subsidiary, Athenex Specialty Products. In this capacity, Mr. Yordon will be responsible for all aspects of the business unit including strategy, new products, manufacturing, distribution, sales and marketing.   Prior to joining Athenex,…

Athenex Announces the Addition of David Cutler, MD, FRCP(C) to its Global Clinical Development Team

Buffalo, NY and Hong Kong – Athenex, Inc. announced today that David Cutler, MD, FRCP(C), has joined Athenex as Vice President of Clinical Development working together with Dr. Rudolf Kwan, Chief Medical Officer. Dr. Cutler has extensive expertise in oncology drug development including a recent leadership position as Distinguished Clinical Scientist, Translational Pharmacology in Merck,…

Antony Leung, Group CEO of Nan Fung Group and former Financial Secretary of Hong Kong Special Administrative Region, to join the Athenex Board of Directors

BUFFALO, N.Y., and HONG KONG — Athenex, Inc announced today that Mr. Antony Leung has accepted the invitation to join the Athenex Board of Directors. Antony Leung, Hon.LLD, GBS, JP, former Financial Secretary of Hong Kong Special Administrative Region, is currently Group CEO of Nan Fung Group, a leading regional conglomerate focusing on property & investment businesses. He is…

Governor Cuomo Announces Major Expansion of Athenex — Creating 1,400 Jobs in Western New York

Athenex (formerly Kinex) to invest $1.62 billion in drug discovery and advanced manufacturing partnership, creating 900 jobs in Dunkirk and 500 jobs in Buffalo over the next ten years. State investing $225 million to support the Buffalo Medical Innovation and Commercialization Hub and help create new opportunities for the region.   Governor Andrew M. Cuomo…

Athenex Announces the Addition of Simon Pedder, PhD and Raymond Yeung, MSc, MBA to its Global Leadership Team

Buffalo, NY and Hong Kong – Athenex, Inc. announced today that Simon Pedder, PhD, has joined Athenex as Vice President of Corporate Strategy and Business Development based in the U.S. and Mr. Raymond Yeung, MSc, MBA has joined as Senior Director and Deputy Head of Clinical Research and Regulatory Affairs, Asia-Pacific, based in Hong Kong.   Dr. Pedder…

Athenex Announces US FDA Allowance of the Investigational New Drug Application of Oradoxel, the Proprietary Oral Form of Docetaxel

Buffalo, NY and Hong Kong- Athenex, Inc. announced today that it has received United States Food and Drug Administration (US FDA) allowance to proceed in the clinic with its proprietary oral form of Docetaxel. This allowance to proceed represents Athenex’s sixth successful oncology investigational new drug (IND) application by the US FDA (5 oral anticancer…

Athenex Announces Progress in Registration Studies of Oral Oncology Drug and China Approvals of Symptom Therapeutic Products

Buffalo, NY and Hong Kong – Athenex, Inc. announced today several significant developments in its proprietary product pipeline within each of its three innovative platforms: Oral Absorption, Kinase Inhibitors and Symptom Therapeutics.   Oral Absorption Platform A pivotal registration study has commenced in the fourth quarter 2015 for Oraxol, the proprietary oral capsule formulation of…

Athenex Announces Recent Business Developments Including the Acquisition of Comprehensive Drug Enterprises

Buffalo, NY and Hong Kong– Athenex, Inc. announces the closing of the acquisition of Comprehensive Drug Enterprises (CDE) based in Hong Kong’s Science Park in a stock for stock transaction closed in July. The CDE platform includes a formulation research and development team based in Hong Kong and a Chongqing manufacturing plant in the Fengdu…

Athenex Completes Public/Private Partnership Agreement with Chongqing, China To Construct Two New Pharmaceutical Manufacturing Plants

Athenex announced today the completion and execution of a definitive agreement with the Banan District in Chongqing, China to construct two separate pharmaceutical manufacturing plants on Banan sites already identified and selected by Athenex management. Under the terms of the agreement, Banan will provide the funding for the land and construction of the manufacturing plants according to Athenex specifications, and Athenex will equip the facilities.